These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1120 related articles for article (PubMed ID: 24380394)

  • 1. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
    Echigoya Y; Yokota T
    Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
    Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
    Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy.
    Miskew Nichols B; Aoki Y; Kuraoka M; Lee JJ; Takeda S; Yokota T
    J Vis Exp; 2016 May; (111):. PubMed ID: 27285612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense oligo-mediated multiple exon skipping in a dog model of duchenne muscular dystrophy.
    Yokota T; Hoffman E; Takeda S
    Methods Mol Biol; 2011; 709():299-312. PubMed ID: 21194037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
    Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
    Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contributions of Japanese patients to development of antisense therapy for DMD.
    Matsuo M; Takeshima Y; Nishio H
    Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide conjugation of 2'-O-methyl phosphorothioate antisense oligonucleotides enhances cardiac uptake and exon skipping in mdx mice.
    Jirka SM; Heemskerk H; Tanganyika-de Winter CL; Muilwijk D; Pang KH; de Visser PC; Janson A; Karnaoukh TG; Vermue R; 't Hoen PA; van Deutekom JC; Aguilera B; Aartsma-Rus A
    Nucleic Acid Ther; 2014 Feb; 24(1):25-36. PubMed ID: 24320790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
    Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
    BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing RNA/ENA chimeric antisense oligonucleotides using in vitro splicing.
    Takeshima Y; Yagi M; Matsuo M
    Methods Mol Biol; 2012; 867():131-41. PubMed ID: 22454059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic Delivery of Morpholinos to Skip Multiple Exons in a Dog Model of Duchenne Muscular Dystrophy.
    Maruyama R; Echigoya Y; Caluseriu O; Aoki Y; Takeda S; Yokota T
    Methods Mol Biol; 2017; 1565():201-213. PubMed ID: 28364245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
    Hanson B; Wood MJA; Roberts TC
    RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exon 51 Skipping Quantification by Digital Droplet PCR in del52hDMD/mdx Mice.
    Hiller M; Spitali P; Datson N; Aartsma-Rus A
    Methods Mol Biol; 2018; 1828():249-262. PubMed ID: 30171546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers.
    Popplewell LJ; Malerba A; Dickson G
    Methods Mol Biol; 2012; 867():143-67. PubMed ID: 22454060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Splice modification to restore functional dystrophin synthesis in Duchenne muscular dystrophy.
    Wilton SD; Fletcher S
    Curr Pharm Des; 2010; 16(8):988-1001. PubMed ID: 20041827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
    Aartsma-Rus A; Fokkema I; Verschuuren J; Ginjaar I; van Deutekom J; van Ommen GJ; den Dunnen JT
    Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
    Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.
    Wang Q; Yin H; Camelliti P; Betts C; Moulton H; Lee H; Saleh AF; Gait MJ; Wood MJ
    J Gene Med; 2010 Apr; 12(4):354-64. PubMed ID: 20235089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse.
    Lu QL; Mann CJ; Lou F; Bou-Gharios G; Morris GE; Xue SA; Fletcher S; Partridge TA; Wilton SD
    Nat Med; 2003 Aug; 9(8):1009-14. PubMed ID: 12847521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.